{
    "nctId": "NCT05590949",
    "briefTitle": "Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors",
    "officialTitle": "Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors and Denosumab: An Observational Study to Assess Rebound Bone Loss and Insufficiency Fractures After Denosumab Discontinuation",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Change in serum carboxy-terminal collagen crosslinks (CTX)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with confirmed diagnosis of breast cancer\n* Participant must be post-menopausal, defined as last menstrual cycle at least 12 months prior to enrollment\n* Received at least 2 doses of denosumab and then discontinued therapy\n* Discontinued AI prior to or within 6 months of last denosumab injection\n* Patients must be 18 years of age or olde\n\nExclusion Criteria:\n\n* Patients with history of osteoporosis prior to starting denosumab, based on previous dual-energy X-ray absorptiometry (DEXA) scan;\n* Patients with history of insufficiency fracture.\n* Patients who continue treatment with a different bone modifying agent (i.e oral or intravenous bisphosphonates) after discontinuation of denosumab\n* Patients on chronic low-dose glucosteroids.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}